Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Key Stats

• Today's Range: $2.71 to $2.90
• 50-Day Range: $1.16 to $4.59
• 52-Week Range: $0.86 to $5.17
• Volume: 1.16 million shs
• Average Volume: 1.39 million shs
• Market Capitalization: $194.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.80
• Consensus Rating: Buy

Aclaris Therapeutics Stock Analysis - MarketRank™

Aclaris Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 241st out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Aclaris Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.75) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aclaris Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aclaris Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aclaris Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.47% of the outstanding shares of Aclaris Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aclaris Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclaris Therapeutics has recently increased by 58.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aclaris Therapeutics does not currently pay a dividend.

Dividend Growth

Aclaris Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.47% of the outstanding shares of Aclaris Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Aclaris Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aclaris Therapeutics has recently increased by 58.97%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.82

News Sentiment

Aclaris Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 18 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.

MarketBeat Follows

6 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aclaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,998.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

Percentage Held by Institutions

98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACRS Stock Analysis - Frequently Asked Questions

How have ACRS shares performed this year?

Aclaris Therapeutics' stock was trading at $1.05 at the beginning of the year. Since then, ACRS shares have increased by 159.0% and is now trading at $2.72.
View the best growth stocks for 2024 here.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.03. The biotechnology company earned $4.35 million during the quarter, compared to the consensus estimate of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative trailing twelve-month return on equity of 40.26%.

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' top institutional investors include BML Capital Management LLC (19.97%), Stonepine Capital Management LLC (3.44%), Trium Capital LLP (2.68%) and Jacobs Levy Equity Management Inc. (1.28%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion, Kevin Balthaser and Frank Ruffo.
View institutional ownership trends.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACRS
• CUSIP: N/A
• CIK: 1557746
• Web: www.aclaristx.com
• Phone: (484) 324-7933
• Fax: 484-320-2344
• Employees: 86
• Year Founded: 2012

Price Target and Rating

• Average Stock Price Target: $8.80
• High Stock Price Target: $13.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +223.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-88,480,000.00
• Net Margins: -136.65%
• Pretax Margin: -138.00%
• Return on Equity: -40.26%
• Return on Assets: -31.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.03
• Quick Ratio: 7.03

Sales & Book Value

• Annual Sales: $27.08 million
• Price / Sales: 7.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.22 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 71,431,000
• Free Float: 66,859,000
• Market Cap: $194.29 million
• Optionable: Optionable
• Beta: 0.45